The objectives of this study are to evaluate the safety, tolerability and efficacy of AT-527 in adult subjects ≥18 years of age with moderate COVID-19 and risk factors for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or matching placebo tablets to be administered orally for 5 days. Local supportive standard of care (SOC) will be allowed for all subjects. Efficacy and safety observations will be compared for treatment with active AT-527 tablets + SOC vs. placebo tablets + SOC.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19
You can join if…
Open to people ages 18 years and up
Hospitalized or in a hospital-affiliated confinement facility
Initial COVID-19 symptom onset within 5 days prior to Screening
SpO2 ≥ 93% on room air or requires ≤ 2L/min oxygen by nasal cannula or mask to maintain SpO2 ≥ 93%
Must also have a history of at least one of the following known risk factors for poor outcomes: obesity (BMI>30), hypertension, diabetes or asthma.
You CAN'T join if...
Severe or critical COVID-19 illness: RR ≥30, HR ≥125, SpO2 <93% on room air or requires >2L/min oxygen by nasal cannula or mask to maintain SpO2 ≥93%, systolic blood pressure < 90 mm Hg, diastolic blood pressure < 60 mm Hg or PaO2/FiO2 <300
Requires mechanical ventilation
Lobar or segmental consolidation on chest imaging.
Treatment with other drugs thought to possibly have activity against SARS-CoV-2
ALT or AST > 5 x upper limit of normal (ULN)
Female subject is pregnant or breastfeeding
Atea Study Siteaccepting new patients Davis California 95817 United States
Atea Study Siteaccepting new patients Los Angeles California 90017 United States